Developer docs
API playgroundTry for free, no card

Search company profiles

OneOme

Full company profile

uuid0003lrx

Namestring
OneOme
Legal namestring
OneOme, LLC
Websiteurl
oneome.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

OneOme was a Minneapolis-based pharmacogenomics (PGx) company co-founded with Mayo Clinic in 2014/2015 to translate genetic variation in drug response into routine clinical decision-making. Its flagship offering, the RightMed Test, used PCR-based analysis of patient DNA (from blood or cheek swab) to interrogate 27 genes and generate medication response insights across 300+ drugs, packaged within the broader RightMed Solution suite that included HIPAA-compliant Provider and Patient Portals, EHR integration and alerts, clinical consults, training, and the RightMed for Populations module targeting payers, PBMs, and employers.

The company commercialized through multiple parallel channels: direct enterprise sales to health systems, channel/reseller relationships (notably Alliance Healthcare Netherlands for Boots and Alphega Pharmacy retail distribution), payer/PBM/employer population health programs (Blue Care Network, Navitus), technology partnerships that embedded RightMed within medication decision support stacks (Tabula Rasa HealthCare, Family Care Path), and direct patient self-pay kits. Revenue mechanics combined one-time test fees billed to insurance (as an out-of-network lab), institutional billing under multi-year contracts, a $349 self-pay price, and a Financial Assistance Program capping out-of-pocket cost at $199 for qualifying patients.

OneOme held a CLIA-certified, CAP-accredited clinical laboratory at its Minneapolis headquarters and was licensed across all U.S. states including high-barrier jurisdictions (New York, California). Backed by early-stage venture firm Invenshure, LLC and Mayo Clinic, the company disclosed approximately $6.39M in funding across three rounds (2015-2017). OneOme ceased PGx testing operations in November 2025 due to financial challenges, and Tempus AI subsequently acquired its pharmacogenetics assets.

Short descriptiontext

OneOme was a Minneapolis-based pharmacogenomics company co-founded with Mayo Clinic that offered the RightMed Test, a 27-gene, 300-medication PGx panel, to health systems, payers, PBMs, employers, and pharmacies before ceasing operations in November 2025.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersMinneapolis, United States
HQ citystring
Minneapolis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
pharmacogenomic testing, clinical laboratory services, precision medicine, genetic medication analysis, population health pharmacogenomics
Industry2 codes
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays
NAICS code3 codes
  • Medical and Diagnostic Laboratories62151
  • Medical Laboratories621511
  • Medical and Diagnostic Laboratories6215
SIC code2 codes
  • Services-Medical Laboratories8071
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Pharmacogenomic Laboratory Testing Services
Social media profiles3 records
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model5 records
1RightMed Test Services
TypeOne Time License
Description

One-time pharmacogenomic laboratory testing services where healthcare providers order tests for patients. Revenue generated from test processing fees billed to insurance, patients directly (self-pay), or institutional accounts. The test analyzes 27 genes to provide medication optimization recommendations.

oneome.com
2Insurance Billing
TypeTransaction Fee
Description

Laboratory billing services submitted to insurance companies on behalf of patients. OneOme is an out-of-network laboratory with most insurance companies. Patients may be responsible for deductibles, coinsurance, and copayments depending on their insurance coverage.

oneome.com
3Patient Self-Pay
TypeOne Time License
Description

Direct patient payment option for those without insurance coverage or who choose not to bill insurance. Currently priced at $349 for self-pay patients.

oneome.com
4Financial Assistance Program
TypeOne Time License
Description

Needs-based assistance program providing access to the RightMed Test for patients who qualify based on household income limits. Qualifying patients have a maximum out-of-pocket cost of $199.

oneome.com
5Institutional/Enterprise Billing
TypeOne Time License
Description

Billing arrangements for health systems, payers, and employer groups implementing population-level PGx programs. Includes check, credit card, or wire transfer payment options.

oneome.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Pricing details4 tiers
1Self-Pay Price
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

$349 for patients choosing to pay directly without insurance billing.

oneome.com
2Financial Assistance Program (FAP) Price
ModelOne time/ perpetual licenseBilling cadencePay-as-you-go
Notes

Maximum out-of-pocket cost of $199 for qualifying patients based on household income limits relative to Federal Poverty Levels. Patient must have insurance but the test is not fully covered.

oneome.com
3Insurance Billing
ModelOtherBilling cadencePay-as-you-go
Notes

Out-of-network with most insurers. Patient responsibility includes deductibles, coinsurance, and copayments. OneOme submits claims and may appeal denials on behalf of patients.

oneome.com
4Institutional Billing
ModelOtherBilling cadenceMulti-year contract
Notes

Available for health systems and organizations. Contact for pricing details.

oneome.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 record
1RightMed
Description

OneOme's flagship pharmacogenomic test and solution platform, including the RightMed Test and RightMed for Populations program.

oneome.com
Core offering1 text field

OneOme provides the RightMed Test, a pharmacogenomic (PGx) test that analyzes 27 genes covering 300+ medications using PCR technology on DNA from cheek swab or blood samples. The RightMed Solution bundles the test with HIPAA-compliant Provider and Patient Portals, clinical consults, EHR integration, and population health modules for health systems, payers, and providers. Tests must be ordered by licensed healthcare providers, and the company operates its own CLIA-certified, CAP-accredited clinical laboratory in Minneapolis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 1 in 3 patients had medication adjusted after PGx testing
+1 more record
Product overview1 text field

OneOme offers the RightMed Solution as its primary product portfolio, centered on the RightMed Test—a pharmacogenomic test analyzing 27 genes for 300+ medications. The RightMed Solution includes complementary clinical consults, Provider and Patient Portals, EHR integration tools, and training programs. For population health management, OneOme offers the RightMed for Populations module targeting payers and employers. The company provides end-to-end pharmacogenomic testing services from sample collection (cheek swab or blood) through interpretation and clinical support.

Product and service4 records
1RightMed Test
CategoryPharmacogenomic Laboratory Testing
Description

A pharmacogenomic laboratory test that analyzes 27 genes from a patient's DNA (via cheek swab or blood) to predict response to 300+ medications. Ordered by licensed healthcare providers to inform medication selection and dosing for individual patients.

2RightMed Solution
CategoryPharmacogenomic Solutions Platform
Description

A bundled suite of products and services for pharmacogenomics, including the RightMed Test, HIPAA-compliant portals, complimentary clinical consults with expert clinicians, training and education programs, and population health capabilities, tailored for payers, healthcare organizations, providers, and patients.

3RightMed for Populations
CategoryPopulation Health Management
Description

A population health module designed for payers, PBMs, and employer groups to leverage pharmacogenomic testing across member populations, aiming to reduce total cost of care and improve patient outcomes through personalized medication decisions at scale.

4Provider and Patient Portals
CategoryClinical Portal Software
Description

HIPAA-compliant web portals for healthcare providers to order tests, access results, and manage patient testing, and for patients to view their pharmacogenomic test reports and manage their testing experience.

Scale indicator7 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2021-04-15
Description

Partnership to combine OneOme's RightMed Test and Interpretation Solutions with TRHC's MedWise medication decision support technology. The combination considers impact of external factors like other medications on gene expression, going beyond traditional single drug-gene pair assessment.

Strategic tierMajorTypeChannel Partner/ Reseller/ DistributorAnnounced on2020-11-13
Description

Expanded agreement to provide RightMed Test to Alliance Healthcare employees (1,500+) and immediate family members as an employee benefit. This built on the earlier pilot program in Netherlands pharmacies.

Strategic tierSignificantTypeStrategic or Co-development PartnerAnnounced on2019-12-02
Description

Partnership to add OneOme's RightMed Test to Family Care Path's MyLegacy genetic wellness application. Results are reviewed with individuals by Family Care Path genetic counselors through CarePathConnect video-based telegenetic service.

Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2019-11-19
Description

Pilot partnership with Alliance Healthcare Netherlands (Walgreens Boots Alliance subsidiary) to bring pharmacogenomic testing to selected Boots and Alphega Pharmacy locations throughout the Netherlands. The pilot evaluated feasibility of offering PGx testing in retail pharmacy settings.

5Blue Care Network
Strategic tierMajorTypeGTM or Marketing Partner
Description

Blue Care Network (Blue Cross Blue Shield of Michigan's HMO) using OneOme's RightMed for Populations program for the Blue Cross Personalized Medicine program. Partnership aimed at reducing total cost of care and improving patient health outcomes.

oneome.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Parmacy benefit management company using OneOme's PGx testing services and providing positive testimonial about quality and cost-effectiveness of the testing.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
1Tempus AI
TypeBroad incumbent
Description

AI-driven precision medicine platform that acquired OneOme's PGx assets in November 2025. Directly comparable as a molecular diagnostics and clinical decision-support company with overlapping technology stack and clinical customer base.

TypeDirect peer
Description

Pharmacogenomic testing company focused on mental health medication selection, offering PGx panels with clinical decision support to providers — directly comparable to OneOme's RightMed test and clinician workflow tools.

TypeBroad incumbent
Description

Established molecular diagnostics company offering genetic and pharmacogenomic tests across multiple therapeutic areas with broad payer relationships. Comparable as a larger incumbent operating in the same clinical genetic testing category.

TypeDirect peer
Description

Clinical genetics company providing population-scale genetic testing including pharmacogenomics to health systems, employers, and payers, with integrated clinical decision support — closely aligned with OneOme's RightMed for Populations go-to-market.

TypeBroad incumbent
Description

Clinical genetic testing company serving clinicians, health systems, and biopharma across hereditary cancer, reproductive health, and pharmacogenomics — comparable as a comprehensive clinical lab with PGx offerings and EHR-integrated reporting.

TypeBroad incumbent
Description

Largest US clinical lab offering a broad menu including pharmacogenomic panels with extensive in-network payer coverage — comparable as a competing PGx provider, though much larger scale and broader test menu than OneOme.

TypeBroad incumbent
Description

Major US clinical laboratory network offering pharmacogenomic testing and comprehensive clinical diagnostics with broad payer contracts — comparable as a competing PGx lab with substantially greater scale and in-network coverage.

TypeBroad incumbent
Description

Clinical genetic testing company spanning oncology, reproductive health, and organ transplant, with clinical decision support tooling and EHR integration — comparable as a specialty clinical lab with similar technology and provider workflow integrations.

TypeBroad incumbent
Description

Oncology-focused molecular diagnostics company acquired by Exact Sciences, offering genomic testing with clinical decision support for therapy selection — comparable as a precision medicine testing company using genetic insights to guide treatment decisions.

TypeRegional player
Description

International clinical laboratory and pathology operator with growing pharmacogenomic testing services, primarily serving Australia/Europe — comparable as a clinical lab offering PGx, though with different geographic footprint than OneOme's US/Netherlands presence.

Market position
Strengths3 records

Each record includes

Headline, Details, Source

Weaknesses3 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers8 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance6 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OneOme

Pharmacogenomic Laboratory Testing Servicesoneome.com

OneOme was a Minneapolis-based pharmacogenomics company co-founded with Mayo Clinic that offered the RightMed Test, a 27-gene, 300-medication PGx panel, to health systems, payers, PBMs, employers, and pharmacies before ceasing operations in November 2025.

What OneOme does

OneOme was a Minneapolis-based pharmacogenomics (PGx) company co-founded with Mayo Clinic in 2014/2015 to translate genetic variation in drug response into routine clinical decision-making. Its flagship offering, the RightMed Test, used PCR-based analysis of patient DNA (from blood or cheek swab) to interrogate 27 genes and generate medication response insights across 300+ drugs, packaged within the broader RightMed Solution suite that included HIPAA-compliant Provider and Patient Portals, EHR integration and alerts, clinical consults, training, and the RightMed for Populations module targeting payers, PBMs, and employers.

The company commercialized through multiple parallel channels: direct enterprise sales to health systems, channel/reseller relationships (notably Alliance Healthcare Netherlands for Boots and Alphega Pharmacy retail distribution), payer/PBM/employer population health programs (Blue Care Network, Navitus), technology partnerships that embedded RightMed within medication decision support stacks (Tabula Rasa HealthCare, Family Care Path), and direct patient self-pay kits. Revenue mechanics combined one-time test fees billed to insurance (as an out-of-network lab), institutional billing under multi-year contracts, a $349 self-pay price, and a Financial Assistance Program capping out-of-pocket cost at $199 for qualifying patients.

OneOme held a CLIA-certified, CAP-accredited clinical laboratory at its Minneapolis headquarters and was licensed across all U.S. states including high-barrier jurisdictions (New York, California). Backed by early-stage venture firm Invenshure, LLC and Mayo Clinic, the company disclosed approximately $6.39M in funding across three rounds (2015-2017). OneOme ceased PGx testing operations in November 2025 due to financial challenges, and Tempus AI subsequently acquired its pharmacogenetics assets.

OneOme firmographics

Firmographics
Name
OneOme
Legal name
OneOme, LLC
Website
https://oneome.com
Company type
Private
Founded year
2015
Operating status
Closed
Headcount range
11–50 employees
Short description
OneOme was a Minneapolis-based pharmacogenomics company co-founded with Mayo Clinic that offered the RightMed Test, a 27-gene, 300-medication PGx panel, to health systems, payers, PBMs, employers, and pharmacies before ceasing operations in November 2025.
Ownership category
akta.pro rank

OneOme industry classification

Industry
Product category
Pharmacogenomic Laboratory Testing Services
NAICS
Medical and Diagnostic Laboratories (62151), Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215)
SIC
Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAANAB
Pharmacogenomics (PGx) Decision Support
SECONDARYHLAAALAN
Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays

Keywords

  • Pharmacogenomic testing
  • Clinical laboratory services
  • Precision medicine
  • Genetic medication analysis
  • Population health pharmacogenomics

Where OneOme is headquartered

Location

Headquarters

HQ city
Minneapolis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

OneOme business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. RightMed Test Services: One-time pharmacogenomic laboratory testing services where healthcare providers order tests for patients. Revenue generated from test processing fees billed to insurance, patients directly (self-pay), or institutional accounts. The test analyzes 27 genes to provide medication optimization recommendations.
  2. Insurance Billing: Laboratory billing services submitted to insurance companies on behalf of patients. OneOme is an out-of-network laboratory with most insurance companies. Patients may be responsible for deductibles, coinsurance, and copayments depending on their insurance coverage.
  3. Patient Self-Pay: Direct patient payment option for those without insurance coverage or who choose not to bill insurance. Currently priced at $349 for self-pay patients.
  4. Financial Assistance Program: Needs-based assistance program providing access to the RightMed Test for patients who qualify based on household income limits. Qualifying patients have a maximum out-of-pocket cost of $199.
  5. Institutional/Enterprise Billing: Billing arrangements for health systems, payers, and employer groups implementing population-level PGx programs. Includes check, credit card, or wire transfer payment options.

Pricing tiers

ModelBillingPrice
One time/ perpetual licensePay-as-you-goSelf-Pay Price
One time/ perpetual licensePay-as-you-goFinancial Assistance Program (FAP) Price
OtherPay-as-you-goInsurance Billing
OtherMulti-year contractInstitutional Billing

Go-to-market motion3 records

Distribution channels4 records

Marketing channels6 records

OneOme product offering

Product offering

Core offering

OneOme provides the RightMed Test, a pharmacogenomic (PGx) test that analyzes 27 genes covering 300+ medications using PCR technology on DNA from cheek swab or blood samples. The RightMed Solution bundles the test with HIPAA-compliant Provider and Patient Portals, clinical consults, EHR integration, and population health modules for health systems, payers, and providers. Tests must be ordered by licensed healthcare providers, and the company operates its own CLIA-certified, CAP-accredited clinical laboratory in Minneapolis.

Product overview

OneOme offers the RightMed Solution as its primary product portfolio, centered on the RightMed Test—a pharmacogenomic test analyzing 27 genes for 300+ medications. The RightMed Solution includes complementary clinical consults, Provider and Patient Portals, EHR integration tools, and training programs. For population health management, OneOme offers the RightMed for Populations module targeting payers and employers. The company provides end-to-end pharmacogenomic testing services from sample collection (cheek swab or blood) through interpretation and clinical support.

Differentiator

Problem solved

Functional benefit

Brands

  • RightMed: OneOme's flagship pharmacogenomic test and solution platform, including the RightMed Test and RightMed for Populations program.

Products and services

  • RightMed Test A pharmacogenomic laboratory test that analyzes 27 genes from a patient's DNA (via cheek swab or blood) to predict response to 300+ medications. Ordered by licensed healthcare providers to inform medication selection and dosing for individual patients.
  • RightMed Solution A bundled suite of products and services for pharmacogenomics, including the RightMed Test, HIPAA-compliant portals, complimentary clinical consults with expert clinicians, training and education programs, and population health capabilities, tailored for payers, healthcare organizations, providers, and patients.
  • RightMed for Populations A population health module designed for payers, PBMs, and employer groups to leverage pharmacogenomic testing across member populations, aiming to reduce total cost of care and improve patient outcomes through personalized medication decisions at scale.
  • Provider and Patient Portals HIPAA-compliant web portals for healthcare providers to order tests, access results, and manage patient testing, and for patients to view their pharmacogenomic test reports and manage their testing experience.

Quantifiable outcome

  • 1 in 3 patients had medication adjusted after PGx testing
  • +1 more outcomes

Companies that use OneOme

Customer profile

Named customers8 records

Segments4 records

Ideal customer profiles3 records

OneOme technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

OneOme partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered major, significant and minor.

  • Tabula Rasa HealthCaremajorStrategic or Co-development Partner · 15 April 2021Partnership to combine OneOme's RightMed Test and Interpretation Solutions with TRHC's MedWise medication decision support technology. The combination considers impact of external factors like other medications on gene expression, going beyond traditional single drug-gene pair assessment.
  • Alliance Healthcare NetherlandsmajorChannel Partner/ Reseller/ Distributor · 13 November 2020Expanded agreement to provide RightMed Test to Alliance Healthcare employees (1,500+) and immediate family members as an employee benefit. This built on the earlier pilot program in Netherlands pharmacies.
  • Family Care PathsignificantStrategic or Co-development Partner · 2 December 2019Partnership to add OneOme's RightMed Test to Family Care Path's MyLegacy genetic wellness application. Results are reviewed with individuals by Family Care Path genetic counselors through CarePathConnect video-based telegenetic service.
  • Alliance Healthcare NetherlandsmajorStrategic or Co-development Partner · 19 November 2019Pilot partnership with Alliance Healthcare Netherlands (Walgreens Boots Alliance subsidiary) to bring pharmacogenomic testing to selected Boots and Alphega Pharmacy locations throughout the Netherlands. The pilot evaluated feasibility of offering PGx testing in retail pharmacy settings.
  • Blue Care NetworkmajorGTM or Marketing PartnerBlue Care Network (Blue Cross Blue Shield of Michigan's HMO) using OneOme's RightMed for Populations program for the Blue Cross Personalized Medicine program. Partnership aimed at reducing total cost of care and improving patient health outcomes.
  • NavitusminorGTM or Marketing PartnerParmacy benefit management company using OneOme's PGx testing services and providing positive testimonial about quality and cost-effectiveness of the testing.

Scale indicators7 records

Recent moves7 records

Expansion highlights5 records

OneOme competitors and assessment

Company assessment

Broad incumbents

  • Tempus AI: AI-driven precision medicine platform that acquired OneOme's PGx assets in November 2025. Directly comparable as a molecular diagnostics and clinical decision-support company with overlapping technology stack and clinical customer base.
  • Myriad Genetics: Established molecular diagnostics company offering genetic and pharmacogenomic tests across multiple therapeutic areas with broad payer relationships. Comparable as a larger incumbent operating in the same clinical genetic testing category.
  • Invitae: Clinical genetic testing company serving clinicians, health systems, and biopharma across hereditary cancer, reproductive health, and pharmacogenomics — comparable as a comprehensive clinical lab with PGx offerings and EHR-integrated reporting.
  • Quest Diagnostics: Largest US clinical lab offering a broad menu including pharmacogenomic panels with extensive in-network payer coverage — comparable as a competing PGx provider, though much larger scale and broader test menu than OneOme.
  • Laboratory Corporation of America (LabCorp): Major US clinical laboratory network offering pharmacogenomic testing and comprehensive clinical diagnostics with broad payer contracts — comparable as a competing PGx lab with substantially greater scale and in-network coverage.
  • Natera: Clinical genetic testing company spanning oncology, reproductive health, and organ transplant, with clinical decision support tooling and EHR integration — comparable as a specialty clinical lab with similar technology and provider workflow integrations.
  • Genomic Health (Exact Sciences): Oncology-focused molecular diagnostics company acquired by Exact Sciences, offering genomic testing with clinical decision support for therapy selection — comparable as a precision medicine testing company using genetic insights to guide treatment decisions.

Direct peers

  • Genomind: Pharmacogenomic testing company focused on mental health medication selection, offering PGx panels with clinical decision support to providers — directly comparable to OneOme's RightMed test and clinician workflow tools.
  • Color Genomics: Clinical genetics company providing population-scale genetic testing including pharmacogenomics to health systems, employers, and payers, with integrated clinical decision support — closely aligned with OneOme's RightMed for Populations go-to-market.

Regional players

  • Sonic Healthcare: International clinical laboratory and pathology operator with growing pharmacogenomic testing services, primarily serving Australia/Europe — comparable as a clinical lab offering PGx, though with different geographic footprint than OneOme's US/Netherlands presence.

Market position

Strengths3 records

Weaknesses3 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

OneOme social profiles

Digital presence

OneOme compliance and trust

Trust signal

Compliance6 records

OneOme financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OneOme leadership team

Management profile

Number of profiles

Profiles7 records

OneOme funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OneOme M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OneOme

What does OneOme do?

OneOme provides the RightMed Test, a pharmacogenomic (PGx) test that analyzes 27 genes covering 300+ medications using PCR technology on DNA from cheek swab or blood samples. The RightMed Solution bundles the test with HIPAA-compliant Provider and Patient Portals, clinical consults, EHR integration, and population health modules for health systems, payers, and providers. Tests must be ordered by licensed healthcare providers, and the company operates its own CLIA-certified, CAP-accredited clinical laboratory in Minneapolis.

Is OneOme a public or private company?

OneOme is a private company. It is classified as venture growth investor backed and is currently closed.

When was OneOme founded?

OneOme was founded in 2015. It employs 11 to 50 people.

Where is OneOme based?

OneOme is headquartered in Minneapolis, United States, in the North America region.

How does OneOme make money?

Five revenue lines are on record. RightMed Test Services are the primary driver. The others are insurance Billing, patient Self-Pay, financial Assistance Program and institutional/Enterprise Billing.

Who are OneOme's main competitors?

Broad incumbents on record are Tempus AI, Myriad Genetics, Invitae, Quest Diagnostics, Laboratory Corporation of America (LabCorp), Natera and Genomic Health (Exact Sciences). Direct peers are Genomind and Color Genomics. Sonic Healthcare is listed as a regional player.

Does OneOme have an API?

No public API is recorded for OneOme.

What industry is OneOme in?

OneOme's product category is Pharmacogenomic Laboratory Testing Services. Its primary akta.pro industry code is HLAAANAB, Pharmacogenomics (PGx) Decision Support, with a secondary code of HLAAALAN, Laboratory Developed Tests (LDTs) & Specialized Clinical Lab Assays. Its NAICS code is 62151 and its SIC code is 8071.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
01netTempus Announces National Launch of OneOme Pharmacogenomics Testing, Advancing Patient Safety and Precision MedicineTempus AI announced the national launch of its OneOme pharmacogenomics testing solution, integrating the acquired platform into its precision medicine portfolio. The new offering includes the RightMed® Comprehensive 27-gene panel and single-gene assays for DPYD and UGT1A1 to help clinicians optimize medication safety and dosing. Results are delivered in under five days, addressing FDA recommendations for genetic testing prior to administering certain chemotherapy therapies.Stock TitanTempus Launches OneOme 27-Gene Pharmacogenomics TestTempus AI, Inc. announced the national launch of its OneOme pharmacogenomics testing solution, featuring a 27-gene RightMed Comprehensive test that analyzes how patients' genetic profiles influence medication response, toxicity risk, and optimal dosing. The launch follows Tempus's acquisition of OneOme in November 2025 and integrates the testing into Tempus's broader precision medicine ecosystem alongside tumor profiling and liquid biopsy capabilities. Results are delivered in under 5 days, addressing clinical needs highlighted by recent FDA labeling updates recommending DPYD testing before common chemotherapy treatments where nearly 30% of patients experience severe or fatal toxicities.ScanXTempus AI launches OneOme pharmacogenomics testing solutionTempus AI has launched the OneOme pharmacogenomics testing solution, following its acquisition of OneOme in November 2025. The new offering provides genetic insights to optimize medication safety, dosing, and toxicity risk assessment. This expansion integrates genomic tumor profiling with treatment processing data to enhance Tempus AI's precision medicine portfolio.GenomeWebTempus Acquiring Pharmacogenetics Assets of Recently Defunct OneOmeTempus AI has acquired the pharmacogenetics assets of OneOme, a Minneapolis-based Mayo Clinic spinoff that shut down operations on Nov. 7 after struggling financially for over a year. The acquisition gives Tempus access to OneOme's 27-gene RightMed PGx test, its CLIA-certified lab infrastructure, and existing partnerships with dozens of US healthcare systems as well as international deals in Canada, Mexico, and Australia. Financial terms were not disclosed, but the move is the latest in a series of acquisitions by Tempus this year as it expands beyond its core cancer molecular testing business into broader genetic testing services.GenomeWebOneOme Closing PGx Testing Operations Due to Financial ChallengesOneOme, a Minneapolis-based pharmacogenomics testing company and Mayo Clinic spinoff, announced it is ceasing operations due to ongoing financial challenges after searching for a buyer for six months without success. The closure will significantly disrupt dozens of healthcare systems that relied on OneOme's RightMed PGx testing, particularly at a time when the FDA recently updated labeling for the chemotherapy Xeloda to recommend pretreatment pharmacogenomic testing. Industry observers note the closure underscores ongoing reimbursement challenges in the PGx testing space, where companies continue to face regulatory scrutiny and coverage hurdles despite some positive legislative developments.Quantum ZeitgeistPrecision Medicine: Using AI and Genomics for Personalized HealthcareThe article reviews the integration of artificial intelligence and genomics into precision medicine, highlighting how these technologies enable personalized therapies through the analysis of multiomics data and genetic variants. It details applications in clinical trials, pharmacogenomics, and cancer diagnosis via liquid biopsies, while noting companies like Invitae and OneOme offering related testing services. The text also discusses emerging gene editing tools such as CRISPR-Cas9 and base editing for treating genetic disorders.MidwestmedicaleditionMinneapolis Based Pharmacogenomics Precision Medicine Company, OneOme, Announces James Kelley, MD, PhD As Chief Medical Officer.OneOme, a Minneapolis-based pharmacogenomics company co-founded by Mayo Clinic, has appointed James Kelley, MD, PhD as its new Chief Medical Officer. Dr. Kelley will lead the company's medical functions, including Medical Affairs and Laboratory Operations, while also managing external regulatory affairs. This leadership change follows an interim period where Dr. Julie England served as CMO before resuming her role as Medical Director of Medical Affairs.PR NewswireTabula Rasa HealthCare and OneOme Combine Powerful Precision Medication Tools to Improve Medication Safety, Efficacy and AdherenceTabula Rasa HealthCare has announced a strategic partnership with OneOme, a pharmacogenomics solutions provider co-founded by Mayo Clinic, to combine their medication safety technologies. The partnership integrates OneOme's RightMed Test and Interpretation Solutions with TRHC's MedWise medication decision support platform to improve medication safety, efficacy, and adherence by considering both genetic and external factors such as other medications and disease states. The combined tools aim to advance precision prescribing across the care continuum and provide greater value for patients, providers, and payors.